Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS

NCT07535242 | Not Yet Recruiting

• 1 other identifier: 2025/426
• Study Type: observational
• Target: 22
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.

Conditions

Multiple Sclerosis

Outcome Measures

Primary Outcomes (7)

• Expanded Disability Status Scale (EDSS)

  The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis. Scores range from 0 to 10, in 0.5-point increments, where 0 indicates normal neurological status and 10 indicates death due to multiple sclerosis. The scale is based on the assessment of functional systems and ambulation, with higher scores reflecting greater disability.

  Baseline

• Standardized Mini-Mental Test

  The Standardized Mini-Mental Test (MMT/MMSE) score ranges from 0 to 30. Higher scores indicate better cognitive function.

  Baseline

• Symbol Digit Modalities Test

  The Symbol Digit Modalities Test (SDMT) is a neuropsychological test used to assess information processing speed, attention, and visual-motor coordination. Score range: Typically 0 to \~110 (number of correct responses in 90 seconds; exact upper limit depends on performance) Higher scores: Indicate better cognitive processing speed and function

  Baseline

• Multiple Sclerosis Impact Scale (MSIS-29)

  Score range: 29-145 (each item scored 1-5) Higher scores: Indicate greater impact of MS on daily life (worse physical and psychological status)

  Baseline

• Glial Fibrillary Acidic Protein (GFAP)

  This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA)

  Baseline

• Neurofilament Light Chain (NfL)

  This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA).

  Baseline

• Vascular Endothelial Growth Factor (VEGF)

  This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA).

  Baseline

Study Arms (1)

Progressive Multiple Sclerosis

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Progressive Multiple Sclerosis

You may qualify if:

• Confirmed diagnosis of MS
• Progressive type MS
• Voluntary participation
• Age between 18-60 years
• Cooperative
• EDSS score ≥ 5.5

You may not qualify if:

• Presence of another neurological disorder
• Change in medication within the last 3 months
• Relapse within the last 3 months

Sponsors & Collaborators

• Ondokuz Mayıs University: lead

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Central Study Contacts

Seda Nur Kemer

CONTACT

+903623121919; sedakemer@gmail.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer, Department of Physiotherapy and Rehabilitation

Study Record Dates

• First Submitted: April 3, 2026
• First Posted: April 17, 2026
• Study Start: April 21, 2026
• Primary Completion: April 30, 2026
• Study Completion: May 5, 2026
• Last Updated: April 17, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share